Article Text

other Versions

Download PDFPDF
Response to: ‘Statins in systemic lupus erythematosus’ by Abud-Mendoza
  1. Hilda J I de Jong1,2,3,
  2. Tjeerd P van Staa3,4,
  3. Jan Willem Cohen Tervaert2,5
  1. 1Centre for Health Protection, National Institute for Public Health and the Environment, Bilthoven, The Netherlands
  2. 2School for Mental Health and Neuroscience, Maastricht University Medical Center, Maastricht, The Netherlands
  3. 3Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Faculty of Sciences, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
  4. 4Health eResearch Centre, Farr Institute for Health Informatics Research, University of Manchester, Manchester, UK
  5. 5Division of Rheumatology, Department of Medicine, University of Alberta, Edmonton, Canada
  1. Correspondence to Dr Jan Willem Cohen Tervaert, School for Mental Health and Neuroscience, Maastricht University Medical Center, 6211 LK Maastricht, The Netherlands; jw.cohentervaert{at}maastrichtuniversity.nl

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

It was with great interest that we read the correspondence of Abud-Mendoza1 on our recent paper in which we described a decreased risk of developing systemic lupus erythematosus (SLE) in statin users who continued their therapy for >1 year.2

We agree that prevention of cardiovascular disease in rheumatic diseases is of great importance.3 Whether statins decrease disease activity in SLE is, however, controversial since a recent meta-analysis of five controlled trials did not suggest any significant effect of statin therapy on Systemic Lupus Erythematosus Disease Activity Index.4

Unfortunately, in the UK’s Clinical Practice Research Datalink (CPRD)—an ongoing primary care database of anonymised medical records from general practitioners that was used in our study—no measurements for SLE activity before or after initiating statin therapy are available.2 We, however, do not think that statin …

View Full Text

Footnotes

  • Handling editor Josef S Smolen

  • Contributors HJIdJ contributed to the concept and design of the study, performed the data analysis, contributed to the interpretation of the results and drafted the letter. TPvS initiated and obtained the funding for the project to which the study presented belongs, contributed to the concept and design of the study, and interpretation of the results, provided background information for the study and reviewed the letter. JWCT contributed to the concept and design of the study, and interpretation of the results, provided background information for the study, and drafted and reviewed the letter.

  • Funding Rijksinstituut voor Volksgezondheid en Milieu. Grant number: research grant S340040.

  • Competing interests None declared.

  • Ethics approval Independent Scientific Advisory Committee for Medicines and Healthcare Products Regulatory Agency (MHRA) Database Research.

  • Provenance and peer review Not commissioned; internally peer reviewed.